These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 27302463)
1. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463 [TBL] [Abstract][Full Text] [Related]
2. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma. Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma. Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263 [TBL] [Abstract][Full Text] [Related]
4. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378 [TBL] [Abstract][Full Text] [Related]
5. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132 [TBL] [Abstract][Full Text] [Related]
6. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312 [TBL] [Abstract][Full Text] [Related]
7. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related]
9. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295 [TBL] [Abstract][Full Text] [Related]
10. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262 [TBL] [Abstract][Full Text] [Related]
11. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852 [TBL] [Abstract][Full Text] [Related]
12. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356 [TBL] [Abstract][Full Text] [Related]
13. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Quintavalle C; Hindupur SK; Quagliata L; Pallante P; Nigro C; Condorelli G; Andersen JB; Tagscherer KE; Roth W; Beguinot F; Heim MH; Ng CKY; Piscuoglio S; Matter MS Cell Death Dis; 2017 Oct; 8(10):e3138. PubMed ID: 29072691 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683 [TBL] [Abstract][Full Text] [Related]
15. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
16. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430 [TBL] [Abstract][Full Text] [Related]
17. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396 [TBL] [Abstract][Full Text] [Related]
18. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785 [TBL] [Abstract][Full Text] [Related]
19. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713 [TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]